NR1H4 and metabolic disease: This review will focus on peroxisome proliferator-activated receptors (PPARs) and farnesoid X receptor (FXR) which have been implicated in hypertension, metabolic diseases, and end organ damage (Jones et al., 2021; Mori, et al., 2022; Rausch, et al., 2022; Hernández-Valdez et al., 2023).